Company intelligence / Profile preview
Chongqing Lummy Pharmaceutical
- Ownership
- Private
- Employees
- ~1019
- Development stage
- Other
Overview
Chongqing Lummy Pharmaceutical develops and manufactures a broad range of pharmaceutical products with strengths in injectables. It has approved drugs for tuberculosis using bacterial replacement therapies and multiple oncology assets in early clinical development. The company also works on cell therapies such as TCR-T cell therapy and therapeutic vaccines targeting cancer. Its pipeline covers anti-tumor agents, anti-infectives including antibiotics that have passed drug consistency evaluation recently, cardiovascular drugs, endocrine/metabolic agents, antifungals, opioid receptor antagonists among others.
- Therapeutic areas
- Infectious DiseasesGastroenterologyEndocrinologyOncologyImmunology
- Modalities
- Small moleculeCell therapyTCR-T cell therapyTherapeutic vaccineChemical drugs
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Chongqing Lummy Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Lummy Pharmaceutical.